ScholarLens Back to search
2020•International Research Journal of PharmacyOpen access

LIGHT CHAIN MULTIPLE MYELOMA: A CASE REPORT

Shamsudeen Moideen, V Maheshwari, Raghuveer Prabhu

Open full text 2 citations

Abstract

Light chain multiple myeloma (LCMM) initiates approximately 15 percentage of patients with multiple myeloma (MM). It has a lower prognosis when compared with the variant immunoglobulin (Ig) G or IgA. We report a rare case on Light chain multiple myeloma in 49-year-old male patient who presented with acute kidney injury, hypercalcemia. histopathology examination was found to be plasmacytoma, kappa restricted; and free kappa lamda chain in urine and serum was found to be greater. Bone pain and renal dysfunction were the most common prevalent initial signs and symptoms while extramedullary disease (EMD) was later acquired during disease. Bortezomib demonstrated superior efficacy over nonbortezomib in LCMM patients.

Open-access reader

About this research paper

What this paper is about

Light chain multiple myeloma (LCMM) initiates approximately 15 percentage of patients with multiple myeloma (MM). It has a lower prognosis when compared with the variant immunoglobulin (Ig) G or IgA. We report a rare case on Light chain multiple myeloma in 49-year-old male patient who presented with acute kidney injury, hypercalcemia. histopathology examination was found to be plasmacytoma, kappa restricted; and free kappa lamda chain in urine and serum was found to be greater. Bone pain and renal dysfunction were the most common prevalent initial signs and symptoms while extramedullary disease (EMD) was later acquired during disease. Bortezomib demonstrated superior efficacy over nonbortezomib in LCMM patients.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Light chain multiple myeloma (LCMM) initiates approximately 15 percentage of patients with multiple myeloma (MM). It has a lower prognosis when compared with the variant immunoglobulin (Ig) G or IgA. We report a rare case on Light chain multiple myeloma in 49-year-old male patient who presented with acute kidney injury, hypercalcemia. histopathology examination was found to be plasmacytoma, kappa restricted; and free kappa lamda chain in urine and serum was found to be greater. Bone pain and renal dysfunction were the most common prevalent initial signs and symptoms while extramedullary disease (EMD) was later acquired during disease. Bortezomib demonstrated superior efficacy over nonbortezomib in LCMM patients.

Key concepts: Multiple myeloma, Immunoglobulin light chain, Medicine, Bence Jones protein, Bortezomib, Plasmacytoma, Kappa, Histopathology

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
LIGHT CHAIN MULTIPLE MYELOMA: A CASE REPORT — Research Paper | ScholarLens